ClinicalTrials.gg
CompletedNCT02903069Updated Apr 19, 2021

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

A Phase 1 interventional study of MRZ and TMZ in Glioblastoma and Malignant Glioma, sponsored by Celgene. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
67th of 221
66 · median 41
Started
2016
with 8 others
Phase 1
70 of 232
3 open now
Registered
161st of 232
by date

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 67th largest by enrollment of the 221 interventional ones that give a count, is one of 9 that started in 2016, is one of 70 in phase 1, and was the 161st registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the growth of the cancer, reducing the size of the tumor, and/or improving survival. Marizomib (MRZ) is being added to standard-of-care treatments of radiotherapy (RT), temozolomide (TMZ), and Optune.

Read the detailed description

Gliomas account for \~80% of primary malignant tumors in the Central Nervous System (CNS), with WHO Grade IV malignant glioma (G4 MG; including glioblastoma and gliosarcoma) constituting the majority of gliomas, and are essentially incurable. Currently only surgical resection and radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) are standard-of-care treatment strategies for newly diagnosed G4 MG. However, resistance to chemotherapy and RT results in a high recurrence rate, with median survival of \~15-16 months. Since no survival advantage has been demonstrated for the addition of bevacizumab (BEV) to TMZ and RT (Chinot 2014) in newly diagnosed G4 MG, alternative promising investigational agents need to be tested.

Targeting the proteasome is a well-validated target for the treatment of multiple myeloma (MM), and preclinical evidence suggests that targeting the proteasome in glioma cells shows significant anti-tumor activity. Proteasome activity is elevated in patient-derived glioblastoma (GBM) tissue in comparison with normal human brain. Importantly, preclinical evidence demonstrates that proteasome inhibition sensitizes GBM cell lines to irradiation and to TMZ. Further, the combination of bortezomib (BTZ, one of three proteasome inhibitors [PI] currently approved for the treatment of MM) with TMZ resulted in synergistic glioblastoma cell death in vitro, and BTZ reduces glioma cell survival in vitro in cell lines sensitive and resistant to TMZ.

Despite the activity against GBM cells in vitro, BTZ does not cross the blood brain barrier, and thus has proven ineffective in animal models and in the clinic. In contrast, marizomib (MRZ) - a potent and irreversible 20S PI possesses the unique attribute among PIs to cross the blood brain barrier as shown in previous clinical studies. These data prompted examination of the combination of MRZ and BEV in an ongoing clinical trial in patients with recurrent G4 MG. In the dose-escalation portion of this ongoing study (MRZ-108), 12 patients were dosed with MRZ once weekly for 3 weeks (0.55, 0.7, and 0.8 mg/m2 infused intravenously (IV) over 10 minutes) and with BEV on weeks 1 and 3 (10 mg/kg IV) of a 28-day cycle. As of April 2016, of these 12 patients, 7 were on study for over 4 months - 5 with a partial response (including 2 patients with no radiologic evidence of tumor on 2 or more consecutive MRI scans) and 2 patients whose best response was stable disease. Four of these 12 patients were treated for over 6 months, 3 of whom remain on study. The recommended Phase 2 dose (RP2D) of MRZ was determined to be 0.8 mg/m2. Currently, an expansion cohort of 24 patients has been enrolled in the Phase 2 portion of the study. The next phase involves treatment with MRZ alone (no BEV) in patients with recurrent G4 MG, and has begun enrolling patients in the second quarter of 2016.

Together, the demonstrated activity of PIs in preclinical glioma models, and the synergistic activity of PIs with TMZ on glioblastoma cells, along with the ability of MRZ to access the CNS, provides compelling rationale to assess the therapeutic benefit of the combination of MRZ with TMZ in patients with G4 MG, for whom no brain-penetrant options for proteasome inhibition are currently available.

Very recently, the FDA has approved a novel treatment device using tumor treating fields (Optune) in addition to standard of care RTand TMZ as an option to standard of care. Optune has been shown to significantly improve both progression-free and overall survival in GBM patients. An additional cohort of 12 patients will be treated with Optune in combination with MRZ and TMZ In North America, the Optune arm is offered only for the US trial sites, and is not offered for the Canadian trial sites.

03

Conditions studied

  • Glioblastoma
  • Malignant Glioma

Keywords

  • newly diagnosed
  • malignant glioma
  • WHO Grade 4
  • WHO Grade IV
  • marizomib
  • MRZ
  • TMZ
  • RT
  • brain cancer
  • proteasome inhibitor
  • radiation
  • temozolomide
  • temodar
  • chemotherapy
  • concurrent
  • adjuvant
  • Optune
  • Novocure
  • NovoTTF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form
  • Males and females of age ≥ 18 years or of age ≥ 22 years for those assigned to Optune™ at the time of signing of the informed consent document.
  • confirmed newly diagnosed G4 MG
  • Performance Status (KPS) score ≥ 70%
  • For Concomitant Treatment: Prior tumor resection or up to 8 weeks prior to first MRZ dose
  • For Treatment: All AEs resulting from surgery must have resolved to (v. 4.03) Grade ≤ 1
  • Stable or decreasing dose of over 14 days prior to first MRZ dose
  • For Concomitant Treatment: No prior treatment with MRZ or any other PIs, including BTZ, carfilzomib (CFZ), or ixazomib (IXZ)
  • For Adjuvant Treatment: No prior treatment with BTZ, CFZ, or IXZ
  • No agent within 4 weeks prior to first dose of study drug
  • Adequate hematological, renal, and hepatic function
  • Patients must be without seizures for at least 14 days prior to enrollment, and patients who receive treatment with AEDs must be on stable doses for at least 14 days prior to enrollment
  • Absence of known infection, chronic , or infection; absence of any other serious medical condition which could interfere with oral medication intake
  • Patients with archival tumor tissue suitable for measurement of proteasome activity and biomarker status must give permission to access and test the tissue. Patients without archival tumor tissue are eligible for the Dose-Escalation stage, but not the Dose-Expansion stage of the study
  • For women of and for men with partners of child-bearing potential, patient must agree to take measures for duration of treatments and for one month after last study treatment
  • Willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Co-medication or concomitant therapy that may interfere with study results
  • History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months
  • Other chemotherapy or anti-tumor treatment for brain tumor (other than therapies required by the inclusion criteria of this protocol)
  • Pregnant or breast feeding
  • Uncontrolled intercurrent illness that would limit compliance with study requirements, or disorders associated with significant state
  • Known other previous/current requiring treatment within ≤ 3 years except for liited disease treated with curative intent
  • Any comorbid condition that confounds the ability to interpret data from the study as judged by the Investigator or Medial Monitor
  • For those enrolled in Treatment with Optune™, patients are excluded if they are \< 22 years of age, have an active implanted medical device, a skull defect, bullet fragments in the head, sensitivity to conductive hydrogels, a scalp condition that might interfere with wearing the device, or GBM that is not supratentorial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Stage 1: Concomitant Treatment

    MRZ + TMZ + RT Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment.

    Drug: MRZ · Drug: TMZ · Radiation: RT

  • Experimental
    Stage 1: Adjuvant Treatment

    MRZ + TMZ

    Drug: MRZ · Drug: TMZ

  • Experimental
    Stage 2: Dose-Expansion

    MRZ + TMZ + RT followed by MRZ + TMZ In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D).

    Drug: MRZ · Drug: TMZ · Radiation: RT

  • Experimental
    Optune Arm

    MRZ + TMZ + Optune

    Drug: MRZ · Drug: TMZ · Device: Optune

Interventions

  • DrugMRZ

    MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment. MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment. IV hydration will be given prior to the MRZ infusion.

    Also known as: NPI-0052

  • DrugTMZ

    TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment. TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment.

    Also known as: temozolomide, Temodar

  • RadiationRT

    Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.

    Also known as: radiation therapy

  • DeviceOptune

    Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.

    Also known as: NovoTTF-100A

06

What researchers measure

Primary outcomes

  1. Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ)

    Assess dose-limiting toxicities (DLTs) in each dose-escalation arm

    Time frame: 42-day concomitant treatment and 28-day Cycle 1 adjuvant treatment

  2. To assess adverse events during the adjuvant treatment

    To assess the safety of the combination of MRZ and TMZ with the addition of Optune™ in patients entering Adjuvant Treatment

    Time frame: From the first dose of study drug through 28 days after the last dose

Secondary outcomes

  1. To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients

    Assess adverse events

    Time frame: Assessments made during the concomitant (dosing for 42 days of a 10-week treatment period) and adjuvant (one or more 28-day cycles) treatment periods in the dose-expansion stage of the study

  2. Assess adverse events during concomitant and adjuvant treatment

    Assess adverse events

    Time frame: From the first dose of study drug through 28 days after the last dose

  3. Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT

    Includes death due to any cause

    Time frame: Survival monitored throughout the concomitant and adjuvant treatment periods and every three months during long-term follow-up for 2 years

  4. Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT

    RANO criteria used to assess tumor response

    Time frame: MRI assessments at Week 10 during concomitant trt and every even Cycle during adjuvant treatment, death monitored throughout the treatment periods, and disease progression and death monitored every three months during long-term follow-up for 2 years

  5. MRZ pharmacokinetics - Maximum Serum Concentration (Cmax)

    Measured after stopping the MRZ infusion

    Time frame: Day 1 and Day 8 during Stage 1 (dose-escalation)

  6. MRZ pharmacokinetics - Elimination Half-Life (t1/2)

    Calculated from MRZ serum concentrations measured through 60 minutes after the stopping the infusion

    Time frame: Day1 and Day 8 during Stage 1 (dose-escalation)

  7. MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf)

    Calculated from MRZ serum concentrations measured through 60 minutes after the stopping the infusion

    Time frame: Day1 and Day 8 during Stage 1 (dose-escalation)

  8. MRZ pharmacokinetics - Clearance (CL)

    Calculated from MRZ serum concentrations measured through 60 minutes after the stopping the infusion

    Time frame: Day1 and Day 8 during Stage 1 (dose-escalation)

  9. MRZ pharmacokinetics - Volume of Distribution (Vd)

    Calculated from MRZ serum concentrations measured through 60 minutes after the stopping the infusion

    Time frame: Day1 and Day 8 during Stage 1 (dose-escalation)

  10. TMZ serum concentration

    Peak and trough TMZ serum concentrations will be measured to see if MRZ affects TMZ serum concentration

    Time frame: On Day 1 of Week 1 (D1) and on Day 1 of Week 2 (D8), TMZ serum concentration will be measured before treatment, and 60 minutes after the dose and 24 hrs after the dose (prior to the Day 9 TMZ dose)

  11. Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)

    Investigator evaluation of neurologic coordination using a standardized rating scale

    Time frame: Assessments made at baseline and then weeks 1, 5, and 8 during concomitant treatment, on Day 1 of each Cycle during adjuvant treatment, and at the end of treatment visit (28 days after last dose of study drug)

  12. Evaluate the activity (overall survival [OS]) of MRZ + TMZ + Optune

    Includes death due to any cause

    Time frame: Survival monitored throughout the concomitant and adjuvant treatment periods and every three months during long-term follow-up for 2 years

  13. Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + Optune

    RANO 2010 criteria used to assess tumor response

    Time frame: MRI assessments at Week 10 during concomitant treatment and every even Cycle during adjuvant treatment, death monitored throughout the treatment periods, and disease progression and death monitored every 3 months during long-term follow-up for 2 years

07

Study locations

8 sites
  • University of California San Diego Medical Center
    La Jolla, California 92037, United States
  • UC Irvine
    Orange, California 92868, United States
  • John Wayne Cancer Center Outpatient Clinic
    Santa Monica, California 90404, United States
  • Northwestern Center For Clinical Research
    Chicago, Illinois 60611, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • Pennsylvania State University College of Medicine
    Hershey, Pennsylvania 17033, United States
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • University of Zurich Hospital
    Zurich, 8091, Switzerland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jan 2021, 53 months.

Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's 53 months is above that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2016
First posted
Sep 16, 2016
StartActual
Aug 17, 2016
Primary completionActual
Jan 25, 2021
CompletionActual
Jan 25, 2021
Last update
Apr 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02903069
Lead sponsor
Celgene
Collaborators
Triphase Research and Development III Corp.
Responsible party
Sponsor
First posted
Sep 16, 2016
Start date
Aug 17, 2016
Primary completion
Jan 25, 2021
Completion
Jan 25, 2021
Last update
Apr 19, 2021

Study contacts

Ileana Elias, M.D.
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion